Thank you very much. We will now begin the question-and-answer session. The first question is from the line of Raman from Sequent Investments.

I just have 2 questions. First of all, one of the question is pertaining to the increase in fee to hospitals during the quarter. There is INR41 crores expense under fee to hospital during the quarter, which has significantly shot up on sequential quarter a s well as year-on-year basis. Yes. So the increase is -- can you just provide an explanation why...

So actually, the -- whilst the accounting nomenclature is fees to hospital, this is also - - the actual increase is on account of Rajasthan project. So for a project like Rajasthan or even other PPP projects, we have certain partners that we work in these remote locations. And there's a certain revenue share amount that goes to these partners. So what you see as an expense is because of lik e the manpower and certain of the operations that they handle and that expense goes in that line. So the increase is probably because of Rajasthan and projects like Manipur and where we have these partners providing us different kind of services.

And can you quantify how much of the revenue has been booked with respect to Rajasthan PPP during this quarter? And going forward for the entire year, how much do we expect will be coming from Rajasthan PPP.

Rajasthan revenue, I think we have rep orted around INR26 crores. And from an annualized basis, I think even if you just multiply this by 4, what number we are expecting is about INR100 crores to INR150 crores of Rajasthan for the full year.

Okay. So you are expecting this INR26 crores t o come for every quarter going forward?

And it will grow. I mean since this is the first quarter of implementation as the labs and other centers go live, the revenue will, of course, double up in the coming quarters. And this is how we expect the business to grow up.

Understood. Sir, I think in the earlier call, you mentioned that you plan to do around INR200 crores to INR250 crores from Rajasthan PPP in FY27. So I just want to understand, is there any particular -- is this guidance intact because you have mentioned that we will be doing only INR150 crores.

No, as I said, from a guidance perspective, we'll prefer to be on a conservative basis. As an aspiration, of course, we want to achieve the numbers that we stated earlier. But if I have to give a guidance, this is something that we have a clear visibility in terms of the revenues that I quoted earlier.

Understood, sir. And...

Mitesh this side, further to add, like we are hoping to get our revenues doubling up in the coming quarter for the Rajasthan I'm talking about. And on a steady state, when we are looking at it, it would be somewhere closer to 150, 175 . And further basis the ramping up, the overall numbers that we have suggested or the previously stated still stand.

Understood, sir. My second question is on the fundraise part. I think promoters has infused funds via warrants. Can you quantify what was the fundraise for?

Could you just repeat the question, please?

So I think the promoter has infused funds via warrant issue. So can you specify why there was a fundraise why there was a promoter infusion.

Yes. it's the warrants was proposed as contribution from the promoter. Two reasons. One is, of course, the funds will be utilized for certain capital expenditure for projects and certain acquisitions that we have in mind, and that was the reason why the funds have been raised.

The next question is from the line of Surya Narayan Patra from PhillipCapital India.

Sorry. Am I audible?

Yes, Mr. Surya, you're audible.

My first question is on the radiology revenue share possibly that since we have implemented new centers now for this quarter, what could be the kind of revenue share that we should be seeing? Can you just let me know that would be the first question.

Okay. Mitesh this side. Yes, as we have added new centers in the radiology as an MRI and certain more are into the pipeline. However, revenue contribution considering radiology and pathology more or less would be in the same line as pathology project for the Rajasthan, which is a huge one, is also getting ramped up. And parallelly, the MRI, which is getting operationalized is also going to ramp up. So for now, we don't see much of a variation coming into the radio versus patho. However, in the coming quarter, we're going to have an detailed understanding how the overall operations are shaping up.

Okay. So then if I just take the earlier quarters' understanding, sir, let's say, around 48% to 50% kind of range for the radiology, then we are seeing a kind of a really strong growth for the radiology business, which is higher than the kind of overall growth that we would have reported. So then should we anticipate kind of a stronger growth for the entire of the year led by radiology, which is generally believed to be a high-margin business?

Yes. So Mr. Surya, our focus is on driving both radiology and pathology together. In terms of the overall contribution, whilst currently, the numbers would be 45%, 55%. I think the way at which Rajasthan would eventually ramp up, if it takes a faster p ace, the balance might tend to go towards pathology.

But both the engines, both radiology also we are focusing. And now with MRIs getting operationalized, we also see the MRI business is ramping up and therefore, the contribution also will come from the MRI business.

Sure, sir. Sir, my second question is about RPL. Congratulations for the kind of a strong progress that you are witnessing in the initial quarter itself. So that is really appreciable. But simultaneously, I just wanted to check whether the RPL is still -- it is in red at the EBITDA level because there is a kind of a drag or there is a kind of a decline only that we have witnessed. As you have in the initial remarks alluded that this is -- could be because largely because o f the Rajasthan. But my question is that, okay, RPL is negative at the EBITDA level or it is already been broken even and contributing to the bottom line.

So RPL, it's currently in the quarter 1, it's at negative EBITDA level for reasons because we have deployed manpower. If you see on the retail side, considering our operations in the 5 states, we have to deploy the ground fleet and that is some of the costs. And like I think it was mentioned by Mitesh as well, by Q2, we expect RPL to also be EBITDA positive. And from there on, it will continue it's upward journey.

Yes. So thanks, Surya, for acknowledging the effort that we are putting up towards the RPL, number one. Secondly, just to add, while yes, there is a drag, but drag has co me down substantially considering the previous few quarters, and it is at a nominal level considering this quarter as in quarter 1. And as Mr. Yash has just mentioned, by quarter 2, we are looking to be breakeven positive for the entire RPL.

Sure, sir. Congratulations for that. And so then, sir, is it possible to give a sense that while we would be seeing relatively lower margin profile for this quarter compared to the kind of the trend that you would have set for our business so far. Here put together led by Rajasthan and led by RPL, what could be the absolute number drag that we would be seeing and which can be covered up in the subsequent period? Can you share that number, sir?

Surya, you're asking from an overall for the Krsnaa Diagnostics company as a whole? The margins we expect to improve from quarter -on-quarter, like Mitesh also alluded earlier, with Rajasthan revenue doubling up in this quarter 2 as we expect as well as RPL getting positive. So overall, the drag will be lesser in the coming quarters, and we see an uptick in the margins going forward as well.

One point on the CGHS, sir. See, I think...

Yash, my question was on just a clarification, radio and pathology 45, 55 this quarter?

It's 41, 59, sorry.

41, 59. So, Yash, if you see radio has been flat revenue wise e ven after the expansion 2 years back from 148 centers to 180 centers, that expansion has not contributed much to the top line of radiology if I go by the revenue mix. What is the problem that you are facing?

What you're saying is there is a sli ght difference in your understanding. The reason is the Rajasthan contribution in this quarter has been significantly higher compared to radiology because the MRI projects have been operationalized over the, let's say, the last 3 months in a staggered manner. So we've not seen the full utilization or full revenue contribution from the MRI projects. And as these projects get up and coming, you will see a contribution. There was also the overall, if you see some of the radiology projects that we lost in the last quarter, they completed their tenure. So that also impact is there. But directionally, radiology is also improving quarter -on-quarter and pathology, just pathology being a larger project, its contribution, the revenue has been higher and that will con tinue in the coming quarters. But as I said, we are aspiration to have both radiology growth in terms of the contribution increasing in the coming quarters as these projects get mature and they get operationalized.

So then is there a change in the mix of your centers where you've added and you've lost some and you've added new. So the matured ones were contributing and now the new ones have come in, so you're kind of flat. Is that the understanding correct?

So from a center count perspe ctive, it's not material. - it's not a material project that we've won. The projects are still there. We still have the same number of, if you see even in the network of radiology centers that we have, they continue. We've added more centers and that revenue ramp -up is still underway. The earlier or the existing centers that are there, they are also growing on a like-like, like I mentioned, they have grown almost 12%, and that we expect to continue to grow in the coming quarters.

The next question is from the line of Aditya Chheda from InCred Asset Management.

This is Pooja Sanghvi. So basically, I wanted to understand the drivers of volume growth versus value growth for this quarter.

Mitesh this side. Volume growth is mainly on account of the expansion that has been carried out, considering in pathology, mainly Rajasthan, in radiology, the new MRI centers, which has been added. Parallelly, in the like -to-like also, it has witness ed a strong growth. That is based on multiple activations, activities and efficiency that we have brought in. Value growth is mainly on account of the new footfalls, which has added and the repeat cycles followed by the -- or backed by the and overall ret ail, which has added the overall value growth too.

Sir, I have one more question. So can you clarify why the fees to the hospital has jumped to the INR40 crores run rate now?

Yes. As I explained earlier, the fees to hospital is n othing but an expense which as Krsnaa Diagnostics, we also partner with certain local partners who have expertise in certain operations, especially considering a large statewide deployment. So there's a certain operations that they undertake. And therefore, there's an expense or revenue sharing that happens to these partners and that expense is sitting in the fees to hospital. So while the nomenclature might not be appropriate, but it's essentially for the Rajasthan project, when the project got l aunched up, some of the activities are undertaken by these partners and therefore, there's a certain revenue share that goes to these partners who work alongside with us in the statewide deployment.

Sir, lastly on the status on receivables of Himachal and Karnataka.

Yes. So on Karnataka, we have received -- the money has started flowing in. There's also approval that we sighted where the state government has approved certain funds and money has started flowing in. Karnataka, it's still not to the expectation that we have. But again, we've received assurances from both the ministries on both these governments, and we are following up in terms of getting the monies.

Pooja rejoin the queue for the follow -up questions. The next question is from the line of Deepak Ajmera from IGE India. As there is no response from the line of Deepak, we'll move to the next that is Vivek Kumar from Bestpals Advisory LLP.

Sir, am I audible?

Yes.

My question regarding retail, how are you -- because you're doing mostly in your Tier 2, I'm assuming this if my assumption is wrong, please correct me. So if you're doing it in Tier 2, Tier 3 locations , how are you trying to get the customers and their trust

because mostly their customers believe they do not go anywhere unless the doctor is prescribed and recommended by the doctor. So how are we building the trust or we are partnering with the doctors? So how is the business model for retail more so in the -- please can you -- what percentage comes from Tier 2, Tier 3 and Tier 4 for our retail business, if you can go in little bit detail, how are we winning customers.

Yes. So it's a good question. In terms of retail, how we are able to attract the se customers. If you see when the places that Krsnaa is present today, like you mentioned, it's in Tier 2, Tier 3 locations, where it's currently not a very strong competitive strength available, number one. Second is when we educate our -- these -- whether it is the franchisees or our touch points that Krsnaa is backed by serving 3 crore s patients, having these highest number of NABL, NABH accreditation in the country today and with strong quality practices in our operations. And that is where the doctors see the value. And of course, then the pricing also becomes an important element as a result of which you have seen the kind of growth that we've been achieving quarter-on-quarter. So as we mentioned earlier, from a DNA perspective, our so -called customer acquisition costs are not significant. We try to rather leverage on the infrastructure, the quality, the accessibility that we build.

So we partner with doctors, right? So that's the understanding.

No, no. We don't partner. We edu cate the doctors that, look, this is a company which has operations in 18 states. These are our quality benchmarks. These are the kind of prices that we offer and of course, then the plethora of the test menu that we have.

But they do not ask for any commission.

Not really. So if you see that in PPP, we have got trust of more than 30,000-plus doctors already existing in our system, right? So our reports, which has been released or authorized for the patient who is coming to a government hospital under any of the NHM scheme the doctor is seeing that and then prescribing the further course of treatment. That particular report itself speaks out loud around the trust that we carry all across, be it is a doctor practicing in govern ment hospitals or the outside the hospitals, number one. Number two rest all what Mr. Yash has mentioned. Be it is the accessibility, affordability backed by the quality because if you see our overall quality standards pan-India are the highest than the nearest peer.

So all these factors plays a lot. And thirdly, to answer or to support that statement today with the increasing awareness all across and even government health care schemes, making people well aware even in the Tier 2, Tier 3 towns. So they ar e also equally educated for getting into the illness prescribed by the doctor or wellness of their own.

Sir, I got it, sir, but just clarification normally Tier 2, Tier 3 doctors have their own partnership with diagnostics. So that is why ther e's a conflict of -- so they get some money from there, right? So how are you able to bypass...

We would not like to comment on...

No. And as a practice, if you see the prices at which we offer and the value, I don't think so there 's a need for any of these kind of associations or practices. We rather focus on the quality of the space.

The next question is from the line of Deepak Ajmera from IGE India.

Am I audible?

Yes.

Yes. So on the Himachal Pradesh part, we have added 22 new locations over there. So what are our future plans and revenue guidance over there? And how are we going to execute in these new locations?

So currently, as I said, it's a new project giving us t he revenue visibility for over a period of 10 years. Like we started with Himachal Pradesh, this additional 22 locations of totally 34 locations is what we will be serving. Predominantly, we are discussing this to be an entirely cash business. And with regards to the revenue and investment, we'll be giving the details more in the coming quarters. There's still some discussions going on. So I'll be able to have more clarity in the coming days and then we'll update you. Maybe we can also discuss this offline as and when the information comes to us.

So beyond Rajasthan, how we going to grow in terms of revenue, if you can just highlight that?

Yes. So if you see from a growth perspective, the like -for-like business, our existing businesses that -- which were established in the previous years, the infrastructure that we have already in place, that will continue to grow. Rajasthan is another engine that we've added in terms of the PPP projects that will further add to the existing base. On top of it, the Himachal Pradesh additional centers

as well as there are some more PP P projects in pipeline, which we envisage which should materialize in the coming quarters will also give us an additional engine of growth. Then there is a third engine , which is the retail business that we've started expanding and that is also showing encouraging results. And we're also launching some innovative products. Like I mentioned earlier, we'll be announcing some new products in the market very soon, which is a blend of diagnostics and some financial protection. So there are these multiple levers, which, in our opinion, should give us a directional growth. And continue the journey upwards.

Okay. And on the margin front, you said the operational efficiency going to kick in, in Rajasthan. So could you please highlight the margins we're going to enjoy this year?

Yes. So from a margin perspective, as I said, we -- once the Rajasthan operation normalizes in terms of the maturity of the opera tion, we expect the margins to come back to double digits at the end of the year as a whole.

And on the retail front, we have achieved INR19 crores, INR20 crores kind of a quarterly run rate. How do you see this going forward?

Mitesh this side. So well, it's an emerging business, and it's -- I should still say that it's just scratching up the surfaces. So by the end of this financial year, we are hoping to go exponentially high with the current run rate. So -- and it's quite encouraging the overall results of the feedback that we are getting it from the market, be it the patients or the doctors and all the differentiators that we have plugged in our system while we were going through the -- going to launch the RPL a year before.

The next question is from the line of Rajat from Tata Mutual Fund.

Am I audible?

Yes, you are audible, Rajat.

Yash, just one observation I have is that if I see your employee expenses, right, for the quarter, despite the starting of Rajasthan tender, right, the employee cost seems to be flat both on a Y-o-Y basis as well as on a quarter-on-quarter basis. I don't know if you have answered this before, but I joined the call a little late.

No, no. So Rajat, i n terms of the employee cost, what has happened is most of the employees what even our CFO mentioned earlier, we came in mostly towards the end

of Q1. And some of the employees are also as part of the partners or the business associates with whom we work, which gets captured under the fees to hospital. And importantly, as management also, we have done some rationalization of the manpower cost, considering, as I said, multiple ways to ensure that we continue to be driving up our margins upwards. So this is how you see. And whilst on a percentage basis, because it's a percentage of revenue, it sees as a lower percentage. But in terms of absolute, there has been an increase. But still, we've been able to control the expense not to have a very major impact on the financial statements.

So going forward, Yash, let's say, next 2 to 3 quarters, do you think employee expenses will be in the similar range? Or as the project ramps up, we'll need to hire more people or the hiring is already done is what I'm trying to understand.

No, there will be some hiring because as I said, some of the labs are still yet to be operationalized, but we will be in tandem with the revenue growth as well. Like the revenue doubles up, I don't think so the impact of the ma npower will be significant in the coming quarters.

The next question is from the line of Pooja from InCred Asset Management.

I was just asking that can you give any guidance on the recovery in the Himachal and Karnataka would it be by the end of Q3 or Q4 or...

. So Pooja on the recovery side, as I said, with Himachal Pradesh, we've already received communication where certain funds have been allocated and that money has already started flowing in. Karnataka, the conversations are going on. there have been various representations. And along with the recent change in the ministry as well, there has been some delay from a procedure perspective, but we expect money to be collected by Q2. So apart from if you see HP, Karnataka and a bit of Maharashtra, all other projects are on track in terms of receiving except for these 3 states where the teams are working ferociously to recover the money that is due from the government.

Okay. Got it, sir. And sir, retail sales is still 8%. So do we expect the mix to improve going forward?

Could you repeat the question, please?

Mitesh this side. Absolutely, and that's where we are working towards because what all network which has already been laid out into the market space as well as the network which is ongoing and th e network which we will going to further laying out into the market. Our contribution what we are looking to target this financial year is to be in the range of 10% to 15%. And going forward, it's further continue to add up to the overall contribution.

The next question is from the line of Surya Narayan Patra from PhillipCapital.

So on the CGHS front, this quarter, we have seen industry peers getting benefited out of it. And possibly for us, it should be a kind of sizable on e. Any benefit of that we have seen, sir?

No. So Surya, the CGHS rates that has been more on the hospital side. Since our rates are contractually as per the tender rate, we don't see it immediately in the current tenders. But the forthcoming tenders still will be benchmarked to the new rates, that is how -- there might be a possibility of getting the upside, but not for the current business.

And just one clarification about the volume growth in fact, while we have seen RPL seeing a kind of robust volume growth, but if we adjust that RPL's volume growth from the reported overall growth, then it looks it is a flat performance for us. So what is impacting whether it is the kind of the effort that you have been following in the l ast couple of quarters to monetize your receivables, whether those efforts continuing and impacting the volume? Or how should one think this number performance in terms of the volumes?

Mitesh this side. So if you see RPL is a business which ha s been diversified and has been operationalized to complement the existing PPP. If you see the overall volume growth, it is both ways, be it is RPL showing higher because of the lower base currently we are having and PPP as an overall business, wherein the base is huge and large and where it is growing at an pace where it is with the adding of the Rajasthan and the MRI are driving the major ones. However, with the existing other businesses, if you see the volumes, volumes are in line with what it should be and adding up to our predefined rates with the government proportionately the values are growing.

No. So, Surya, if you see from a volume growth perspective, as I said, in the PPP, the ramp-up sometimes happens exponentially, right, because these are underserved areas. So the volume growth would not necessarily be in the same the way industry moves. Our business model is differentiated. Our presence is in different locations compared to what the peers would have been. So I wouldn't say it's an apple -to-apple comparison. Yes, but from a direction perspective, both retail and on the PPP side, volumes have grown and they continue to grow. And that also is reflected in both from a revenue perspective. Like what Mitesh also mentioned earlier in terms of the retail, we are seeing a huge uptick in the acceptance and people have started accepting retail wellness packages, illnes s packages. And similarly on the PPP side with Rajasthan and other the radiology projects, the volumes continue to grow.

Thank you. Ladies and gentlemen, due to time constraints that was last question. I would now like to hand the conference over to the management for closing comments.

Thank you. Sumit, I hope we've been able to address all your questions today. If there are any queries that remain unanswered or if you require any further information, please feel free to reach out to our Investor Relations teams, and we'll be happy to assist. Thank you once again for joining us today and for your continued interest and support in Krsnaa Diagnostics. We look forward to speaking with you again in the next quarter. Thank you.

Thank you. On behalf of Equirus Securities Private Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.